Citadel Advisors
SYRS

Citadel Advisors’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Citadel Advisors’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-26,622
Closed -$95.6K – 15500
2024
Q2 		$137K Buy
+26,622
New +$140K ﹤0.01% 10470
2024
Q1 		– Sell
-6,180
Closed -$42.7K – 15621
2023
Q4 		$48.1K Buy
+6,180
New +$21.2K ﹤0.01% 11815
2022
Q3 		– Sell
-2,239
Closed -$22K – 13816
2022
Q2 		$22K Sell
2,239
-10,571
-83% -$98.9K ﹤0.01% 12373
2022
Q1 		$152K Buy
12,810
+6,475
+102% +$116K ﹤0.01% 11845
2021
Q4 		$206K Sell
6,335
-618
-9% -$25K ﹤0.01% 11789
2021
Q3 		$311K Sell
6,953
-1,172
-14% -$57.2K ﹤0.01% 11004
2021
Q2 		$443K Sell
8,125
-61,703
-88% -$3.65M ﹤0.01% 10323
2021
Q1 		$5.22M Buy
69,828
+59,400
+570% +$6.17M ﹤0.01% 4158
2020
Q4 		$1.13M Buy
+10,428
New +$952K ﹤0.01% 6542
2020
Q3 		– Sell
-1,258
Closed -$134K – 10880
2020
Q2 		$134K Buy
+1,258
New +$113K ﹤0.01% 8818
2019
Q1 		– Sell
-2,376
Closed -$132K – 9989
2018
Q4 		$132K Buy
+2,376
New +$181K ﹤0.01% 8123
2018
Q3 		– Sell
-1,821
Closed -$186K – 9803
2018
Q2 		$186K Buy
+1,821
New +$226K ﹤0.01% 7941
2017
Q4 		– Sell
-6,625
Closed -$975K – 8529
2017
Q3 		$975K Buy
+6,625
New +$1.25M ﹤0.01% 4357

Other funds holding SYRS

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
1CM
1492 Capital Management Milwaukee, Wisconsin $263M AUM 61.9% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Citadel Advisors's SYRS Position: Q3 2024 in Review

Citadel Advisors sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q3 2024, closing a stake of 26,622 shares — an estimated $95.6K sold.

Citadel Advisors first reported a position in SYRS in Q3 2017 and held it in 13 quarters. The position peaked at $5.22M in Q1 2021. 65 funds tracked by Wall St. Rank hold SYRS as of Q3 2024.

  • Citadel Advisors reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Citadel Advisors sold 26,622 Syros Pharmaceuticals, Inc. Common Stock shares in Q3 2024, an estimated $95.6K.
  • Citadel Advisors first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q3 2017 and held it in 13 quarters.
  • Citadel Advisors's Syros Pharmaceuticals, Inc. Common Stock position peaked at $5.22M in Q1 2021.
  • 65 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q3 2024.

Based on Citadel Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.